Investigational drug · Phase 2
TST001
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Advanced Cancer, Gastric Cancer, Gastroesophageal-junction Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 29, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
5
Any phase or sponsor naming "TST001"
First trial start
2020
May 28, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TST001", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Cancer
- Gastric Cancer
- Gastroesophageal-junction Cancer
- Pancreatic Cancer
Approved drugs for the same conditions: Pancreatic cancer · Stomach and esophageal cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "TST001" as an intervention, largest first.
- Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ AdenocarcinomaPivotal-lookingNot yet recruiting
Transcenta Therapeutics (Hangzhou) Co., Ltd.Industry
NCT06093425 · 820 participants (planned) · Start Jun 30, 2027 · Primary completion Oct 1, 2029
Drug: Pembrolizumab and either Capcecitabine + Oxaliplatin or Oxaliplatin+Leucovorin + 5-fluorouracil; Pembrolizumab and either Capcecitabine + Oxaliplatin or Oxaliplatin+Leucovorin + 5-fluorouracil · For: Gastric Cancer; Gastroesophageal-junction Cancer; Advanced Cancer
- A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid TumorsActive, not recruiting
Transcenta Therapeutics (Hangzhou) Co., Ltd.Industry
NCT04495296 · 320 participants (planned) · Start Aug 13, 2020 · Primary completion Jun 30, 2027
Drug: TST001; Oxaliplatin and 5 more · For: Advanced Cancer
Sites: Bengbu, China; Beijing, China; Chongqing, China · 40 sites in all
- A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid TumorsActive, not recruiting
Transcenta Therapeutics (Hangzhou) Co., Ltd.Industry
NCT04396821 · 150 participants (planned) · Start May 28, 2020 · Primary completion Jun 30, 2027
Drug: TST001; Nivolumab Injection [Opdivo] and 3 more · For: Advanced Cancer; Gastric Cancer; Gastroesophageal-junction Cancer and 1 more
Sites: Gilbert, Arizona; Tucson, Arizona; New Haven, Connecticut · 18 sites in all
Henan Cancer HospitalGovernment (non-federal)
NCT05608785 · 45 participants (planned) · Start Jan 1, 2023 · Primary completion Dec 31, 2023
Drug: IBI315; Oxaliplatin and 4 more · For: Gastric Cancer; Gastroesophageal-junction Cancer
Shanghai Zhongshan HospitalAcademic, hospital or other
NCT05190575 · 8 participants · Start Jan 14, 2022 · Primary completion May 6, 2023
Drug: TST001 · For: Biliary Tract Neoplasms
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
- CLDN18.2 targeting enhances chemotherapy sensitivity in pancreatic cancer cells and lung cancer organoids.
Zhang Z, Fu J, Li X, et al. · Biochem Biophys Res Commun 2026
- A case report of a patient with advanced gastric adenocarcinoma who demonstrated excellent long-term sustained efficacy even after discontinuation of treatment following chemotherapy combined with claudin18.2 and PD-1 therapy.
Yu S, Zhu H · Front Pharmacol 2026
- [177Lu]Lu-labeled anti-claudin-18.2 antibody demonstrated radioimmunotherapy potential in gastric cancer mouse xenograft models.
Zeng Z, Li L, Tao J, et al. · Eur J Nucl Med Mol Imaging 2024
- Development of a CLDN18.2-targeting immuno-PET probe for non-invasive imaging in gastrointestinal tumors.
Chen Y, Hou X, Li D, et al. · J Pharm Anal 2023
Also in development for Advanced Cancer
- ObrixtamigBI 764532Phase 36 trials
Boehringer Ingelheim · Small Cell Lung Cancer, Large Cell Neuroendocrine Lung Carcinoma, Extrapulmonary Neuroendocrine Carcinoma of Small Cell Histology
- EzabenlimabBI 754091Phase 32 trials
Boehringer Ingelheim · Advanced Cancer, Neoplasm Metastasis, Advanced Tumors
- ALK201Phase 22 trials
Shanghai Allink Biotherapeutics Co., Ltd. · NSCLC (Advanced Non-small Cell Lung Cancer), Advanced Cancer, Advanced Solid Tumors
- CVM-1118TRX-818Phase 22 trials
TaiRx, Inc. · Hepatocellular Carcinoma, Advanced Cancer, Neuroendocrine Tumors
- KB707Phase 22 trials
Krystal Biotech, Inc. · Cancer, Melanoma Stage III, Melanoma Stage IV
- LY188011Phase 22 trials
Eli Lilly · Neoplasms, Child, Adolescent
- Personalized Neoantigen Peptide VaccinePhase 22 trials
Seqker Biosciences, Inc. · Solid Tumors, Advanced Cancer, Recurrent Cancer
- APL-101Phase 21 trial
Apollomics Inc. · Solid Tumors, Advanced Cancer, Renal Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.